Short answer
Boston Scientific (BSX) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $5.2B (up 11.6% year over year) with net income of $1.3B.
Q1 2026 key financials · XBRL
- Revenue
- $5.2B
- +11.6% YoY
- Net income
- $1.3B
- +99.0% YoY
- Operating margin
- 21.2%
- Gross margin
- 69.5%
- EPS (diluted)
- $0.90
- +100.0% YoY
Source: XBRL data from the Boston Scientific (BSX) Q1 2026 10-Q on SEC EDGAR. USD.
Boston Scientific Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash position, operating cash flow, and capital deployment not discussed
- Near-term outlook, guidance, and emerging headwinds not included
Risk Factors
- No material changes to risk factors from most recent Form 10-K
- Penumbra merger exposure following January 14, 2026 merger agreement
- Acquisition financing risk following February 26, 2026 credit and term-loan agreements
- CEO trading-plan termination covering up to 478,914 shares on February 19, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.